Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

29 Nov 2018

Abstract excerpt

BACKGROUND: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels. METHODS: A phase II randomized clinical trial of 123 patients with Her2-negative breast cancer was conducted, with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Breast Lesions and Carcinomas
Share to Cancer Treatment and Pharmacology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30497530
DOI: 10.1186/s13073-018-0601-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrationsPMID 30497530Read ↗

Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancerSemantic proximity Read ↗

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Semantic proximity Read ↗

An integrated ‘omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumabSemantic proximity Read ↗

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).Semantic proximity Read ↗

Annexin A2 Mediates Bevacizumab Resistance and Infiltrative Escape in GlioblastomaSemantic proximity Read ↗

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.Semantic proximity Read ↗

Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma.Semantic proximity Read ↗

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.Semantic proximity Read ↗

Efficacy and Safety of Bevacizumab-Containing Therapy in Refractory Advanced Breast Cancer：A Retrospective StudySemantic proximity Read ↗

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast CancerSemantic proximity Read ↗

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Semantic proximity Read ↗

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.